AF
AVIR icon

Amalgamated Financial’s Atea Pharmaceuticals AVIR Stock Holding History

Amalgamated Financial’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$58K Buy
+8,080
New +$54.9K ﹤0.01% 2351

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Financial's AVIR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2022: 8,080 shares worth $58K. The stake represents ﹤0.01% of the portfolio and ranks #2351 among its holdings.

127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

  • Amalgamated Financial held 8,080 shares of Atea Pharmaceuticals worth $58K as of Q1 2022.
  • Atea Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Atea Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2351 holding.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.